Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes - Trial NCT06293664
Access comprehensive clinical trial information for NCT06293664 through Pure Global AI's free database. This phase not specified trial is sponsored by Dasman Diabetes Institute and is currently Recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 13 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dasman Diabetes Institute
Timeline & Enrollment
N/A
Mar 04, 2024
Apr 04, 2024
Primary Outcome
Difference in the total or incremental area under the curve of glucose and insulin concentration at an OGTT during saline vs. ฮฑ-MSH infusion
Summary
Alpha-melanocyte stimulatory hormone (ฮฑ-MSH) is a melanocyte-stimulating hormone produced by
 the hypothalamus and released from the pituitary gland. It acts as an agonist to the
 melanocortin 5 receptor (MC5R) in human skeletal muscle, playing a role in glucose uptake and
 disposal. This study aims to investigate whether ฮฑ-MSH can enhance glucose tolerance in
 patients with Type 2 Diabetes Mellitus (T2DM).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06293664
Non-Device Trial